Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytyc invests in endometriosis

This article was originally published in The Gray Sheet

Executive Summary

Women's healthcare firm views a less-invasive, serum-based diagnostic test presently being developed by Valeo Medical for detecting endometriosis as having "excellent potential" to become a successful product. Cytyc announced making an equity investment in Valeo Nov. 9. A Valeo spokesperson says the firm is in preclinical development for the test, having completed feasibility studies on more than 450 human samples demonstrating acceptable levels of specificity and sensitivity. An estimated 7 mil. women suffer from endometriosis in the U.S. each year. Cytyc extended its women's health portfolio with a $325 mil. acquisition of NovaSure menorrhagia treatment manufacturer Novacept on March 1 (1"The Gray Sheet" March 8, 2004, p. 21)...

You may also be interested in...

Cytyc Expands Women’s Health Niche With Novacept Menorrhagia Treatment

Cytyc will double its sales force targeting ob/gyn physicians to 200 reps following its acquisition of Novacept, in an effort to make NovaSure the top-selling menorrhagia treatment system

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts